Insider Buying: Aardvark Therapeutics, Inc. (NASDAQ:AARD) CFO Acquires $160,000.00 in Stock

Aardvark Therapeutics, Inc. (NASDAQ:AARD) CFO Nelson Sun bought 10,000 shares of the stock in a transaction on Friday, February 14th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $160,000.00. Following the purchase, the chief financial officer now owns 99,484 shares in the company, valued at $1,591,744. This trade represents a 11.18 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.

Aardvark Therapeutics Stock Performance

Aardvark Therapeutics stock opened at $14.02 on Friday. Aardvark Therapeutics, Inc. has a 12-month low of $11.55 and a 12-month high of $19.58.

About Aardvark Therapeutics

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.